Lamivudine compared with newer antivirals for prophylaxis of hepatitis B core antibody positive livers: a cost-effectiveness analysis.
about
KASL clinical practice guidelines: management of chronic hepatitis BAdverse effects of oral antiviral therapy in chronic hepatitis B.Donor-derived infection--the challenge for transplant safety.Effective but costly: How to tackle difficult trade-offs in evaluating health improving technologies in liver diseases.Solid organ transplantation from hepatitis B virus-positive donors: consensus guidelines for recipient management.Hepatitis B Virus Infection and Organ Transplantation.
P2860
Lamivudine compared with newer antivirals for prophylaxis of hepatitis B core antibody positive livers: a cost-effectiveness analysis.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Lamivudine compared with newer ...... a cost-effectiveness analysis.
@en
Lamivudine compared with newer ...... a cost-effectiveness analysis.
@nl
type
label
Lamivudine compared with newer ...... a cost-effectiveness analysis.
@en
Lamivudine compared with newer ...... a cost-effectiveness analysis.
@nl
prefLabel
Lamivudine compared with newer ...... a cost-effectiveness analysis.
@en
Lamivudine compared with newer ...... a cost-effectiveness analysis.
@nl
P2093
P2860
P356
P1476
Lamivudine compared with newer ...... a cost-effectiveness analysis.
@en
P2093
A J Wright
J A Fishman
P2860
P304
P356
10.1111/AJT.12598
P407
P577
2014-01-24T00:00:00Z